These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

767 related articles for article (PubMed ID: 7810426)

  • 1. Development of active immunity in newborn pigs with colostral antibodies by vaccination with gIII-deleted PRV.
    Kit S; Kit M; McConnell S; Lawhorn B
    Acta Vet Hung; 1994; 42(2-3):319-30. PubMed ID: 7810426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circumvention of maternal antibody interference by immunization of newborn pigs with glycoprotein gIII-deleted marker vaccine.
    Kit S; McConnell S; Kit M; Lawhorn B
    Immunol Cell Biol; 1993 Oct; 71 ( Pt 5)():421-30. PubMed ID: 8270271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination of newborn pigs in the presence of low levels of pseudorabies colostral antibodies.
    Lawhorn B; McConnell S; Kit M; Kit S
    Vaccine; 1994 May; 12(7):601-6. PubMed ID: 8085376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An approach to a FMD vaccine based on genetic engineered attenuated pseudorabies virus: one experiment using VP1 gene alone generates an antibody responds on FMD and pseudorabies in swine.
    Qian P; Li XM; Jin ML; Peng GQ; Chen HC
    Vaccine; 2004 Jun; 22(17-18):2129-36. PubMed ID: 15149769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High- and low-challenge exposure doses used to compare intranasal and intramuscular administration of pseudorabies virus vaccine in passively immune pigs.
    Arellano PE; Morrison RB; Molitor TW; Thawley DG
    J Am Vet Med Assoc; 1992 Mar; 200(5):685-91. PubMed ID: 1314793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a recombinant vaccinia virus containing pseudorabies (PR) virus glycoprotein genes gp50, gII, and gIII as a PR vaccine for pigs.
    Mengeling WL; Brockmeier SL; Lager KM
    Arch Virol; 1994; 134(3-4):259-69. PubMed ID: 8129615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of specific humoral immune response in pigs vaccinated intradermally with deleted Aujeszky's disease vaccine and challenged with virulent strain of Herpesvirus suis type 1.
    Mikulska-Skupień E; Szweda W; Procajło Z
    Pol J Vet Sci; 2005; 8(1):11-6. PubMed ID: 15794468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody response of pigs to inactivated monovalent and bivalent vaccines for porcine parvovirus and pseudorabies virus.
    Mengeling WL; Gutekunst DE; Pirtle EC
    Am J Vet Res; 1980 Oct; 41(10):1569-71. PubMed ID: 6261613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination against pseudorabies with glycoprotein gI+ or glycoprotein gI- vaccine.
    Vandeputte J; Chappuis G; Fargeaud D; Précausta P; Guillemin F; Brun A; Desmettre P; Stellmann C
    Am J Vet Res; 1990 Jul; 51(7):1100-6. PubMed ID: 2167620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody response to glycoprotein I in maternally immune pigs exposed to a mildly virulent strain of pseudorabies virus.
    van Oirschot JT; Daus F; Kimman TG; van Zaane D
    Am J Vet Res; 1991 Nov; 52(11):1788-93. PubMed ID: 1664670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of an Aujeszky's disease vaccine based on deletion mutant strain 783 which does not express thymidine kinase and glycoprotein I.
    van Oirschot JT; Terpstra C; Moormann RJ; Berns AJ; Gielkens AL
    Vet Rec; 1990 Nov; 127(18):443-6. PubMed ID: 2177288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Field trial to evaluate the immunogenicity of pseudorabies virus vaccines with deletions for glycoproteins G and E.
    Firkins LD; Weigel RM; Biehl LG; Hahn EC
    Am J Vet Res; 1997 Sep; 58(9):976-84. PubMed ID: 9285001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Constancy of Aujeszky's field virus antibody titres in sows repeatedly vaccinated with a gI-negative vaccine.
    Hopp W; Jungblut R
    Acta Vet Hung; 1994; 42(2-3):409-11. PubMed ID: 7810439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination of swine with thymidine kinase-deficient mutants of pseudorabies virus.
    McGregor S; Easterday BC; Kaplan AS; Ben-Porat T
    Am J Vet Res; 1985 Jul; 46(7):1494-7. PubMed ID: 2992326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-generation pseudorabies virus vaccine with deletions in thymidine kinase and glycoprotein genes.
    Kit S; Sheppard M; Ichimura H; Kit M
    Am J Vet Res; 1987 May; 48(5):780-93. PubMed ID: 3035972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune response of pigs inoculated with virulent pseudorabies virus and pigs inoculated with attenuated or inactivated pseudorabies virus vaccine before and after challenge exposure.
    Kelling CL; Staudinger WL; Rhodes MB
    Am J Vet Res; 1982 Dec; 43(12):2114-20. PubMed ID: 6299139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the safety and efficacy of a thymidine kinase, inverted repeat, gI, and gpX gene-deleted pseudorabies vaccine.
    Swenson SL; McMillen J; Hill HT
    J Vet Diagn Invest; 1993 Jul; 5(3):341-6. PubMed ID: 8396983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal vaccination of pigs against pseudorabies: absence of vaccinal virus latency and failure to prevent latency of virulent virus.
    van Oirschot JT; Gielkens AL
    Am J Vet Res; 1984 Oct; 45(10):2099-103. PubMed ID: 6093645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection against pseudorabies virus infection by intranasal vaccination of newborn pigs.
    McCaw MB; Xu J
    Am J Vet Res; 1993 Apr; 54(4):527-33. PubMed ID: 8387249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental infection of fattening pigs with pseudorabies (Aujeszky's disease) virus: efficacy of attenuated live- and inactivated-virus vaccines in pigs with or without passive immunity.
    Vannier P
    Am J Vet Res; 1985 Jul; 46(7):1498-502. PubMed ID: 2992327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.